The treatment of acute lymphoblastic leukaemia (ALL) in childhood has become progressively both more successful and more intensive and thus possibly associated with more short and long term toxicity.' Induction and intensification treatment are associated with myelosuppression and gastrointestinal toxicity, both predisposing to bacterial and sometimes fungal infections, while both cranial irradiation and continuing (maintenance) treatment are immunosuppressive,2 3 thus predisposing to non-bacterial infections. We have reviewed the causes of death in remission in three consecutive cohorts of children treated at the Hospitals for Sick Children to determine whether the pattern of such deaths had changed with increasing intensity of treatment over the years and to identify those patients who might be deemed at special risk of death in remission.
Patients and methods
The patients comprise all of the children referred to the Hospitals for Sick Children for treatment of ALL from 1972 to 1989 inclusive. Most of the patients in the first cohort were the subject of a previous paper.4
All children received induction treatment with prednisolone, vincristine and colaspase, frequently with additional drugs, all received central nervous system directed treatment with intrathecal methotrexate and cranial irradiation, deferred in those under 2 and omitted in those under 1 year from 1985 onwards and all received continuing (maintenance) chemotherapy for at least two years. The continuing treatment comprised 6-mercaptopurine and methotrexate with prednisolone and vincristine and, in the earlier protocols, some additional drugs.
The protocols for treatment had become progressively more intensive over the years but the patients could conveniently be assigned to one of three groups according to the years of diagnosis.
From 1972-8 (group 1) patients received early MRC UKALL protocols II-IV which have been reviewed in detail elsewhere.5
From 1979-82 (group 2) children with B-precursor ALL received our PLOD protocol described in detail previously,6 while those with T cell ALL were treated on a multidrug Remission was not achieved in 17 children. Measles, or presumed measles, was the single There were 11 deaths without remission in most common cause of death in groups 1 and group 1, five from Gram negative sepsis as pre-2, all but one child had an interstitial pneuviously described,'1 two from complications of monia; the remaining girl had an encephalitis. a high leucocyte count and hyperviscosity There have been no fatal cases from 1983 (leucostasis) and haemorrhage, and four who onwards. The single case of fatal chickenpox failed to respond to chemotherapy. Four occurred in group 1 and two children have children had early deaths in group 2, one from died from disseminated herpes simplex infechepatic failure and sepsis, and two from tion, one in group 1 and one in group 3. There leucostasis and bleeding, while one child failed were three cases of cytomegalovirus infection to respond to chemotherapy. One child in in group 1; one child dying from cytogroup 3 died from Escherichia coli septicaemia megalovirus pneumonia during treatment, and during induction and one from leucostasis.
one developing chronic respiratory failure who The overall survival rate, as shown in table died within a year of electively stopping treat-1, has improved steadily during this time ment. The third child, who was blind from cytomegalovirus retinitis and who excreted but three children died in group 3. One death Four children have developed second malignancies. One had secondary myelodysplasia with monosomy 7 and one boy developed a parietal glioma. The third child, with a family history of neurofibromatosis, two of whose siblings subsequently developed mediastinal non-Hodgkin's lymphoma, presented with ALL of early pre-B subtype, and then developed a lymphoblastic lymphoma of the mediastinum.
The fourth patient, a girl with T cell ALL, developed an illness with some features of haemophagocytic lymphohistiocytosis but postmortem examination confirmed a diagnosis of Langerhans cell histiocytosis.
Discussion
This analysis of all children treated at a single centre during 18 years shows, as expected, that there has been a highly significant improvement in survival for children with ALL. The early death rate remains low and is less than 1% despite increased intensity of induction treatment. However, the rate of remission deaths has not changed and remains between 5 and 6%. There has, however, been a change in the pattern of remission deaths which is illustrated by our results and we have also been able to identify certain vulnerable groups of patients.
The first of these are children under 2 years, and infants in particular. Infants under the age of 1 year with ALL have an extremely high relapse rate12 13 and our attempts to intensify treatment have included further high dose consolidation and bone marrow transplantation. It is significant that two recent deaths in infants occurred from gut toxicity during intensification and two from adenoviral infection after bone marrow transplantation. While attempts to improve prognosis in this high risk group of patients are clearly justified, the protocols require constant modification in the light of toxicity and availability of a high level of supportive care.
The second group are children with Down's syndrome, whose vulnerability we have previously noted. 14 These children have a pre-existing immunodeficiency,15 which is presumably exacerbated by continuing chemotherapy. It is of interest that both deaths were apparently associated with mycoplasma pneumonitis.
The third group of children are those undergoing bone marrow transplantation in first remission. Bone marrow transplantation reduces the risk of relapse in a select group of high risk patients with ALL'6 but is associated with a greater morbidity and mortality, thus emphasising the need for careful selection of patients at highest risk of treatment failure.
The change in protocols over the years has been accompanied by a change in the pattern of remission deaths. The classical maintenance or continuing treatment given to children with ALL is immunosuppressive rather than myelosuppressive2 and thus increases susceptibility to non-bacterial infections. These were classically measles and herpes virus infections, together with P carinii pneumonitis. Fortunately all of these infections have become less important as a cause of death in remission. The fall in measles infections in our population, which preceded the introduction of measles, mumps and rubella vaccine, should happily now be sustained, thus eliminating one of the most serious and untreatable infections.
No child has died with chickenpox for over 17 years thanks to the availability of acyclovir and zoster immunoglobulin. Herpes simplex is responsive to treatment with acyclovir and deaths should be preventable by liberal early use of the drug in children with severe and or recurrent oral herpes. It is of interest that two of the three deaths associated with cytomegalovirus infection occurred in children who had received several granulocyte transfusions and that there have been no deaths in recent years.
Our original approach to diagnosis of P carinii pneumonitis with a strict policy of early lung biopsy was followed by reluctance to use this investigation after the introduction of cotrimoxazole for treatment. Both the deaths from pneumocystis pneumonitis occurred in children who had failed to respond to cotrimoxazole and in whom extensive investigation was pursued rather late. More recently, the routine use of prophylactic co-trimoxazole, bronchioalveolar lavage in diagnosis and steroids in selected cases, have improved prevention, diagnosis, and treatment. '7 Over half the deaths in groups 1 and 2 were due to these four types of non-bacterial infection. There was a significant change in the pattern in children in group 3 where only one of the 17 deaths occurred from herpes simplex infection but there was a miscellany of other causes, many of which could be attributed to further intensification of treatment.
The introduction of further intensification treatment after children have achieved remission increases the risk of bacterial infection as during induction, and, dependent on We are grateful to our colleagues in histopathology for histological review, to our microbiology colleagues and especially
